RecruitingNot ApplicableNCT05631405
Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)
Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone
Sponsor
Chulalongkorn University
Enrollment
200 participants
Start Date
Oct 16, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this randomized double-blinded placebo-controlled trial is to learn about dexamethasone and the treatment of severe dengue population. The main question it aims to answer are steroid therapy may be effective in dengue.
Eligibility
Min Age: 7 YearsMax Age: 99 Years
Inclusion Criteria6
- Laboratory confirmed Dengue infected patients (Positive NS1 Ag or anti-DENV IgM by Dengue Duo test)
- And still in febrile phase (Body temp>37.5 C)
- Shock : Sys<90mmHg or Narrow PP (<20mmHg) orTachycardia (pulse>100/min) with Hematocrit decreased ≥20 %
- Fluid accumulation and respiratory distress
- Severe bleeding
- Severe organ involvement
Exclusion Criteria4
- Severe dengue> 24 hrs
- Dengue without warning signs
- Pregnancy
- Patient who receieved any steroid within 1 week
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDexamethasone
Patients treated with dexamethasone
DRUGPlacebo
Patients treated with placebo
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05631405